Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
Recruiting · NCT06976892 · Registry updated 2025-08-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 1 | 2025-08-13 | NCT06976892 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Algok Bio Inc. | 1 |
| Institute of Cancer Research, United Kingdom | 59 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Addenbrooke's Hospital | Cambridge | United Kingdom | 1 |
| Royal Marsden Hospital - Drug Development Unit | Sutton | United Kingdom | 1 |
| Velindre Cancer Centre | Cardiff | United Kingdom | 2 |